NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clementia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.35 0.00 (0.00 %) (As of 08/16/2019 01:21 PM ET) Add Compare Today's Range$26.35Now: $26.35▼$26.3550-Day Range$26.35MA: $26.35▼$26.3552-Week Range$8.10Now: $26.35▼$26.73VolumeN/AAverage Volume145,059 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/ABeta0.64 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMTA Previous Symbol CUSIPN/A CIK1647320 Webhttp://www.clementiapharma.com/ Phone514-940-3600Debt Debt-to-Equity RatioN/A Current Ratio14.03 Quick Ratio14.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book5.09Profitability EPS (Most Recent Fiscal Year)($7.93) Net Income$-58,130,000.00 Net MarginsN/A Return on Equity-44.73% Return on Assets-41.66%Miscellaneous Employees30 Outstanding Shares38,060,000Market Cap$1.00 billion Next Earnings DateN/A OptionableNot Optionable NASDAQ:CMTA Rates by TradingView Receive CMTA News and Ratings via Email Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter. Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions What is Clementia Pharmaceuticals' stock symbol? Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA." How were Clementia Pharmaceuticals' earnings last quarter? Clementia Pharmaceuticals Inc (NASDAQ:CMTA) posted its earnings results on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04. View Clementia Pharmaceuticals' Earnings History. What price target have analysts set for CMTA? 4 brokerages have issued 1 year target prices for Clementia Pharmaceuticals' shares. Their forecasts range from $26.00 to $27.00. On average, they expect Clementia Pharmaceuticals' stock price to reach $26.50 in the next year. This suggests a possible upside of 0.6% from the stock's current price. View Analyst Price Targets for Clementia Pharmaceuticals. What is the consensus analysts' recommendation for Clementia Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clementia Pharmaceuticals. Has Clementia Pharmaceuticals been receiving favorable news coverage? News stories about CMTA stock have trended negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clementia Pharmaceuticals earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Clementia Pharmaceuticals. Who are some of Clementia Pharmaceuticals' key competitors? Some companies that are related to Clementia Pharmaceuticals include FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA) and PTC Therapeutics (PTCT). What other stocks do shareholders of Clementia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), JPMorgan Chase & Co. (JPM), Exelixis (EXEL), Eyepoint Pharmaceuticals (EYPT), Amicus Therapeutics (FOLD), Myokardia (MYOK) and Nektar Therapeutics (NKTR). Who are Clementia Pharmaceuticals' key executives? Clementia Pharmaceuticals' management team includes the folowing people: Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)Mr. Jeffrey Packman, Chief Devel. Officer (Age 52)Mr. Steve Forte, CFO & Corp. Sec. (Age 40)Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50) When did Clementia Pharmaceuticals IPO? (CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers. What is Clementia Pharmaceuticals' stock price today? One share of CMTA stock can currently be purchased for approximately $26.35. How big of a company is Clementia Pharmaceuticals? Clementia Pharmaceuticals has a market capitalization of $1.00 billion. The company earns $-58,130,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.View Additional Information About Clementia Pharmaceuticals. What is Clementia Pharmaceuticals' official website? The official website for Clementia Pharmaceuticals is http://www.clementiapharma.com/. How can I contact Clementia Pharmaceuticals? Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected] MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 169 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 368MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/18/2019 by MarketBeat.com StaffFeatured Article: What is a CD ladder?